

Bangkok Chain Hospital

(BCH.BK/BCH TB)*

Outperform · Maintained

Price as of 26 Jan 2021	14.70
12M target price (Bt/shr)	22.30
Unchanged/Revised up(down)(%)	Unchanged
Upside/downside (%)	51.7

Key messages

เราคาดว่ากำไรสุทธิของ BCH ใน 4Q63F จะอยู่ที่ 328 ล้านบาท (+36.3% YoY, -20.6% QoQ) ซึ่งหากผลประกอบการเป็นไปตามคาด กำไรสุทธิใน 4Q63F และในปี 2563F จะคิดเป็น 27.4% และ 106.9% ของประมาณการกำไรทั้งปีของเราที่ 1.19 พันล้านบาท ทั้งนี้ BCH สามารถชดเชยผลกระทบจากการเน้นตรวจ COVID-19 เราจึงยังคงประมาณการกำไรสุทธิปี 2563F เอาไว้ที่ 1.19 พันล้านบาท (+5.5% YoY) และปี 2564F ไว้ที่ 1.36 พันล้านบาท (+13.5% YoY) เรายังคงคำแนะนำซื้อ และให้ราคาเป้าหมาย DCF ที่ 22.30 บาท


Trading data

Mkt cap (Btbn/US\$m)	36/1,223		
Outstanding shares (mn)	2,494		
Foreign ownership (mn)	273		
3M avg. daily trading (mn)	13		
52-week trading range (Bt)	10.6-15.8		
Performance (%)	3M	6M	12M
Absolute	4.3	(2.7)	(7.6)
Relative	(15.8)	(14.3)	(5.8)

Quarterly EPS

Bt	Q1	Q2	Q3	Q4
2017	0.07	0.07	0.12	0.11
2018	0.09	0.10	0.14	0.11
2019	0.10	0.10	0.16	0.10
2020	0.10	0.11	0.17	

Share price chart



Source: SET

Parin Kitchatornpitak
66.2658.8888 Ext. 8858
parink@kgi.co.th

ประมาณการ 4Q63F: คาดผลการดำเนินงานจะออกมาดี

Event

ประมาณการ 4Q63

Impact

คาดว่าผลประกอบการของ BCH ใน 4Q63 จะดีขึ้น YoY

เราคาดว่ากำไรสุทธิของ BCH ใน 4Q63F จะอยู่ที่ 328 ล้านบาท (+36.3% YoY, -20.6% QoQ) ซึ่งหากผลประกอบการเป็นไปตามคาด กำไรสุทธิใน 4Q63F และในปี 2563F จะคิดเป็น 27.4% และ 106.9% ของประมาณการกำไรทั้งปีของเราที่ 1.19 พันล้านบาท ทั้งนี้ ในกรณีของ BCH เห็นได้ชัดว่า บริษัทไม่ได้ถูกกระทบจากการที่ COVID-19 ระบาดมาตั้งแต่ 2Q63 เพราะบริษัทมีรายได้เพิ่มขึ้นจาก i) การตรวจ COVID-19 ii) การให้บริการกักตัวของรัฐแบบทางเลือก (alternative state quarantine หรือ ASQ) และ iii) การให้บริการรักษาผู้ป่วยประกันสังคม ซึ่งเราคาดว่าแนวโน้มธุรกิจในปี 4Q63 ก็จะยังคงเหมือนเดิม เพราะเราคาดว่ารายได้จากธุรกิจโรงพยาบาลของ BCH จะอยู่ที่ 2.33 พันล้านบาท (+6.0% YoY, -1.3% QoQ) ในขณะที่คาดว่าอัตรากำไรขั้นต้นจะอยู่ที่ 32.5% เพิ่มขึ้น YoY จากรายได้ประกันสังคมที่เพิ่มขึ้น แต่ลดลง QoQ ตามปัจจัยฤดูกาล เราคาดว่าสัดส่วน SG&A/ยอดขายจะอยู่ที่ 12.0% ลดลง YoY แต่เพิ่มขึ้น QoQ ทั้งนี้ BCH ได้อานิสงส์เต็มปีจากการปรับเพิ่มค่ารักษาพยาบาลกลุ่มประกันสังคมในปี 2563 และไม่ได้รับผลกระทบจาก HCC ใน 4Q63 รวมทั้งดีแรงหนุนจากการตรวจ COVID-19

คาดว่าผลการดำเนินงานจะดีขึ้นต่อเนื่องในปี 2564

กำไรสุทธิของ BCH ในงวด 9M63 เติบโตอย่างแข็งแกร่งถึง 6.4% YoY ทั้งนี้ เราคาดว่ากำไรสุทธิใน 4Q63 จะโตอย่างมีนัยสำคัญถึง 36.3% YoY ในปี 2564 เราคาดว่าผลการดำเนินงานจะถูกขับเคลื่อนโดย i) ฐานรายได้ที่แข็งแกร่งของบริการ SSO ii) ผลการดำเนินงานที่ดีขึ้นของ WMC (ตามจำนวนผู้ป่วยต่างชาติที่เพิ่มขึ้นตั้งแต่ 4Q63) และ iii) ผลการดำเนินงานที่แข็งแกร่งของ KH Ramkamheang

ลงประมาณการกำไรปี FY63-64

จากมุมมองของเราต่อผลประกอบการ 4Q63F และแนวโน้มธุรกิจปี 2564 เราจึงยังคงประมาณการกำไรสุทธิปี 2563F เอาไว้ที่ 1.19 พันล้านบาท (+5.5% YoY) และปี 2564F ไว้ที่ 1.36 พันล้านบาท (+13.5% YoY) เราคิดว่าประมาณการของเราสะท้อนถึง i) การชะลอตัวของเศรษฐกิจ ii) จำนวนผู้ป่วยตัวนอกกลางที่เพิ่มขึ้นเล็กน้อยในปี 2564 และ iii) การระบาดของ COVID-19 และความเป็นไปได้ของการนำวัคซีนมาใช้ โดยสรุปแล้ว เราชอบ BCH ในแง่ของกลยุทธ์ธุรกิจที่ดี จากการเน้นตรวจ COVID-19 ซึ่งทำให้มีรายได้เพิ่มขึ้นจนสามารถชดเชยผลจากการที่ผู้ป่วยต่างชาติของ WMC ลดลงได้

Valuation & Action

เรายังคงคำแนะนำซื้อ และให้ราคาเป้าหมาย DCF ที่ 22.30 บาท

Risks

COVID-19 ระบาด, เกิดปัญหาเสถียรภาพทางการเมืองไทยรอบใหม่, และเกิดเหตุก่อการร้ายครั้งใหญ่

Key financials and valuations

	Dec-17A	Dec-18A	Dec-19A	Dec-20F	Dec-21F
Revenue (Bt mn)	7,255	8,073	8,880	9,318	10,249
Gross profit (Bt mn)	2,378	2,679	2,828	2,982	3,382
EBIT (Bt mn)	1,526	1,659	1,715	1,854	2,091
Net profit (Bt mn)	917	1,089	1,135	1,197	1,359
EPS (Bt)	0.37	0.44	0.46	0.48	0.54
DPS (Bt)	0.12	0.12	0.11	0.12	0.14
EPS growth (%)	21.8	18.8	4.2	5.5	13.5
P/E (x)	40.0	33.7	32.3	30.6	27.0
P/B (x)	6.2	5.7	5.3	5.2	4.9
EV/EBITDA (x)	19.4	18.2	17.3	16.2	14.6
Net Debt to Equity (%)	58.0	61.8	65.9	65.8	61.5
Dividend Yield (%)	0.8	0.8	0.8	0.8	0.9
Return on Avg. Equity (%)	15.5	17.0	16.3	16.9	18.3

Source: Company data, KGI Research

Figure 1: BCH's 4Q20 earnings forecast

Bt mn	4Q20F	4Q19	YoY (%)	3Q20	QoQ (%)	2020F	2019	YoY (%)
Sale revenue	2,328	2,196	6.0	2,359	(1.3)	8,947	8,880	0.8
Operating cost	(1,571)	(1,535)	2.3	(1,496)	5.0	(5,975)	(6,052)	(1.3)
Gross profit	757	661	14.5	863	(12.3)	2,973	2,828	5.1
SG&A	(279)	(320)	(12.7)	(276)	1.2	(1,129)	(1,232)	(8.4)
EBIT	497	369	34.9	606	(18.0)	1,925	1,715	12.2
Net profit	328	241	36.3	413	(20.6)	1,280	1,135	12.7
EPS (Bt)	0.13	0.10	36.3	0.17	(20.6)	0.51	0.46	12.7
Percent	4Q20F	4Q19	YoY (ppts)	3Q20	QoQ (ppts)	2020F	2019	YoY (ppts)
Gross margin	32.5	30.1	2.4	36.6	(4.1)	33.2	31.8	1.4
SG&A/Sales	12.0	14.6	(2.6)	11.7	0.3	12.6	13.9	(1.3)
Net profit margin	14.1	11.0	3.1	17.5	(3.4)	14.3	12.8	1.5

	4Q20F	4Q19	YoY (%)	3Q20	QoQ (%)
<i>Revenue by hospital breakdown</i>					
Kasemrad (Bt mn)	1,918	1,768	8.5	1,958	(2.0)
Karunvej (Bt mn)	154	127	20.6	165	(7.0)
WMC (Bt mn)	256	301	(14.9)	236	8.6
<i>Revenue by patient type</i>					
OPD (Bt mn)	908	681	33.4	915	(0.8)
IPD (Bt mn)	535	751	(28.7)	530	1.0
SS (Bt mn)	885	764	15.7	913	(3.1)

	4Q20F	4Q19	YoY (ppts)	3Q20	QoQ (ppts)
<i>Revenue by hospital breakdown</i>					
Kasemrad (%)	82.4	80.5	1.9	83.0	(0.6)
Karunvej (%)	6.6	5.8	0.8	7.0	(0.4)
WMC (%)	11.0	13.7	(2.7)	10.0	1.0
<i>Revenue by patient type</i>					
OPD (%)	39.0	31.0	8.0	38.8	0.2
IPD (%)	23.0	34.2	(11.2)	22.5	0.5
SS (%)	38.0	34.8	3.2	38.7	(0.7)

Source: Company data, KGI Research


Figure 2: WMC's revenue per bill

	2014	2015	2016	2017	2018	2019	9M19	9M20
Thai OPD (Bt)	2,500	2,635	2,720	2,950	2,900	2,950	2,830	3,955
Foreign OPD (Bt)	4,540	6,250	8,180	9,650	8,455	7,680	7,835	8,930
Thai IPD (Bt)	44,330	43,190	45,955	61,130	60,800	53,100	52,480	55,700
Foreign iPD (Bt)	180,980	180,360	218,640	261,300	815,900	1,192,000	1,152,210	1,812,190
IPD Length of stay - Thai (days)	2.2	2.2	2.2	2.2	2.1	2.5	2.5	2.6
IPD Length of stay - Foreign (days)	4.3	3.5	4.6	5.9	15.8	22.2	22.5	29.3
Thai IPD per day (Bt)	20,150	19,632	20,889	27,786	28,952	21,240	20,992	21,423
Foreign IPD per day (Bt)	42,088	51,531	47,530	44,288	51,639	53,694	51,209	61,849

Source: Company data, KGI Research


Figure 3: WMC's revenue mix by patients' nationality

Unit: Mb.



Source: Company data

Figure 4: Projects in pipeline (as of November 15, 2020)




Source: Company data, KGI Research

Figure 5: COVID-19 vaccine's development (as of November 17, 2020)








Source: The Standard Co.

Figure 6: Level of excellence



Source: Company data, KGI Research

Figure 7: Hospital brands

	Hospital Brands	#Hospitals	#Beds
	World Medical Hospital (WMC)	1	150
	Kasemrad International Hospital (KIH)	2	184
	Kasemrad Hospital (KH)	8	1,390
	Karunvej Hospital (KV)	2	305
TOTAL		13	2,029


Source: Company data, KGI Research

Figure 8: Company profile

Bangkok Chain Hospital (BCH) was established in 1993 with initial capital of Bt150mn. In 2013, the company expanded with three additional hospitals including i) World Medical Hospital (WMH) on Chaengwattana Road, which focuses on the high-end market from both local and international patients with international standards and modern medical equipment, and ii) acquisition of two Navanakorn Hospitals in Pathumthani and Ayudhaya. Currently, the company operates 11 hospitals and two poly clinics within the network with 2,328 registered beds. The company serves all types of customers both in Bangkok and upcountry.


Source: Company data

Figure 9: Shareholding structure




Source: Company data, KGI Research

Figure 10: Revenue contribution by brand in 2018




Source: Company data, KGI Research

Figure 11: Revenue contribution by brand in 2019




Source: Company data, KGI Research

Figure 12: Revenue contribution by patient type in 2018




Source: Company data, KGI Research

Figure 13: Revenue contribution by patient type in 2019




Source: Company data, KGI Research

Figure 14: WMC's 2019 revenue breakdown by nationality



Source: Company data, KGI Research

Figure 15: PE band



Source: Bloomberg, KGI Research

Quarterly Income Statement

	Mar-17A	Jun-17A	Sep-17A	Dec-17A	Mar-18A	Jun-18A	Sep-18A	Dec-18A	Mar-19A	Jun-19A	Sep-19A	Dec-19A	Mar-20A	Jun-20A	Sep-20A
Income Statement (Bt mn)															
Revenue	1,622	1,676	2,004	1,953	1,822	1,918	2,228	2,105	2,078	2,137	2,469	2,196	2,178	2,083	2,359
Cost of Goods Sold	(1,154)	(1,140)	(1,299)	(1,283)	(1,250)	(1,277)	(1,432)	(1,435)	(1,444)	(1,483)	(1,590)	(1,535)	(1,515)	(1,392)	(1,496)
Gross Profit	468	536	704	670	573	641	796	670	635	654	879	661	663	691	863
Operating Expenses	(209)	(271)	(226)	(254)	(255)	(288)	(300)	(289)	(288)	(306)	(317)	(320)	(293)	(280)	(276)
Other incomes	26	27	16	38	22	27	27	35	28	30	32	28	20	21	20
Operating Profit	285	292	495	455	340	380	523	416	374	378	594	369	389	432	606
Non-Operating Income															
Interest Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Non-op Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-Operating Expenses															
Interest Expense	(39)	(28)	(34)	(35)	(33)	(30)	(31)	(32)	(32)	(34)	(35)	(29)	(30)	(32)	(35)
Other Non-op Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Investment Income/(Loss)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pre-tax Profit	246	264	460	420	307	350	492	384	342	343	559	339	359	399	572
Current taxation	(40)	(51)	(95)	(85)	(53)	(62)	(88)	(82)	(59)	(65)	(101)	(62)	(63)	(75)	(107)
Minorities	(41)	(40)	(63)	(57)	(39)	(38)	(47)	(34)	(35)	(36)	(56)	(36)	(37)	(46)	(52)
Extraordinary items	-	(0)	-	0	-	0	-	(0)	-	1	-	(1)	-	1	-
Net Profit	165	172	303	278	215	250	357	268	248	244	402	241	259	279	413
EPS (Bt)	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.1	0.1	0.2
Margins (%)															
Gross profit margin	28.8	32.0	35.2	34.3	31.4	33.4	35.7	31.8	30.5	30.6	35.6	30.1	30.4	33.2	36.6
Operating margin	17.6	17.4	24.7	23.3	18.7	19.8	23.5	19.8	18.0	17.7	24.1	16.8	17.9	20.7	25.7
Net profit margin	10.2	10.3	15.1	14.2	11.8	13.0	16.0	12.8	11.9	11.4	16.3	11.0	11.9	13.4	17.5
Growth (%)															
Revenue growth	5.2	9.5	14.7	15.4	12.4	14.4	11.2	7.8	14.0	11.4	10.8	4.3	4.8	(2.5)	(4.5)
Operating growth	(3.4)	0.8	27.9	36.7	19.4	30.3	5.7	(8.5)	10.0	(0.5)	13.6	(11.4)	4.0	14.2	2.1
Net profit growth	5.8	10.0	24.4	40.3	30.2	45.3	17.8	(3.4)	15.6	(2.4)	12.8	(10.3)	4.4	14.3	2.8

Source: KGI Research

Balance Sheet

As of 31 Dec (Bt mn)	2017	2018	2019	2020F	2021F
Total Assets	12,674	12,627	14,116	14,448	15,129
Current Assets	3,364	2,549	2,967	3,064	3,504
Cash & ST Investments	486	646	792	888	1,122
Inventories	204	238	231	280	303
Accounts Receivable	1,091	1,564	1,853	1,805	1,985
Others	1,583	101	90	92	95
Non-current Assets	9,310	10,079	11,149	11,383	11,624
LT Investments	1,024	1,010	1,006	1,006	1,006
Net fixed Assets	7,887	8,665	9,944	10,170	10,402
Others	400	404	198	208	216
Total Liabilities	6,762	6,230	7,137	7,386	7,704
Current Liabilities	2,276	1,740	2,186	2,372	2,579
Accounts Payable	567	792	852	930	1,008
ST Borrowings	1,150	346	718	765	826
Others	559	602	615	677	745
Long-term Liabilities	4,486	4,489	4,952	5,014	5,125
Long-term Debts	4,344	4,354	4,759	4,855	4,952
Others	142	136	192	159	173
Shareholders' Equity	5,912	6,398	6,978	7,061	7,425
Common Stock	2,494	2,494	2,494	2,494	2,494
Capital Surplus	645	645	645	645	645
Retained Earnings	1,837	2,352	2,935	3,349	3,990
Others	936	908	905	574	297

Source: KGI Research

Key Ratios

Year to 31 Dec (Bt mn)	2017	2018	2019	2020F	2021F
Growth (% YoY)					
Sales	11.4	11.3	10.0	4.9	10.0
OP	17.0	8.7	3.4	8.1	12.8
EBITDA	13.5	8.3	6.5	7.3	10.6
NP	21.8	18.8	4.2	5.5	13.5
EPS	21.8	18.8	4.2	5.5	13.5
Profitability (%)					
Gross Margin	32.8	33.2	31.8	32.0	33.0
Operating Margin	21.0	20.5	19.3	19.9	20.4
EBITDA Margin	28.4	27.7	26.8	27.4	27.6
Net Profit Margin	12.6	13.5	12.8	12.8	13.3
ROAA	7.2	8.6	8.0	8.3	9.0
ROAE	15.5	17.0	16.3	16.9	18.3
Stability					
Gross Debt/Equity (%)	92.9	73.5	78.5	79.6	77.8
Net Debt/Equity (%)	58.0	61.8	65.9	65.8	61.5
Interest Coverage (x)	8.0	11.2	13.2	13.1	13.8
Interest & ST Debt Coverage (x)	1.2	3.5	2.0	2.1	2.2
Cash Flow Interest Coverage (x)	13.3	12.9	14.6	14.9	16.0
Cash Flow/Interest & ST Debt (x)	1.4	3.4	2.2	2.2	2.3
Current Ratio (x)	1.5	1.5	1.4	1.3	1.4
Quick Ratio (x)	1.4	1.3	1.3	1.2	1.2
Net Debt (Bt mn)	5,151	4,190	4,877	4,891	4,829
Per Share Data (Bt)					
EPS	0.4	0.4	0.5	0.5	0.5
CFPS	0.2	0.3	0.3	0.4	0.4
BVPS	2.4	2.6	2.8	2.8	3.0
SPS	2.9	3.2	3.6	3.7	4.1
EBITDA/Share	0.8	0.9	1.0	1.0	1.1
DPS	0.1	0.1	0.1	0.1	0.1
Activity					
Asset Turnover (x)	0.6	0.6	0.7	0.7	0.7
Days Receivables	54.9	70.7	76.2	70.7	70.7
Days Inventory	10.3	10.8	9.5	11.0	10.8
Days Payable	42.5	53.6	51.4	53.6	53.6
Cash Cycle	22.7	27.9	34.3	28.1	27.9

Source: KGI Research

Profit & Loss

Year to 31 Dec (Bt mn)	2017	2018	2019	2020F	2021F
Sales	7,255	8,073	8,880	9,318	10,249
Cost of Goods Sold	(4,877)	(5,394)	(6,052)	(6,336)	(6,867)
Gross Profit	2,378	2,679	2,828	2,982	3,382
Operating Expenses	(852)	(1,020)	(1,114)	(1,127)	(1,291)
Operating Profit	1,526	1,659	1,715	1,854	2,091
Net Interest	(136)	(126)	(131)	(135)	(139)
Interest Income	0	0	0	0	0
Interest Expense	(136)	(126)	(131)	(135)	(139)
Net Investment Income/(Loss)	0	0	0	0	0
Net other Non-op. Income/(Loss)	108	112	118	130	143
Net Extraordinaries	(202)	(159)	(163)	(179)	(203)
Pretax Income	1,390	1,533	1,584	1,720	1,952
Income Taxes	(271)	(285)	(286)	(344)	(390)
Net Profit	917	1,089	1,135	1,197	1,359
EBITDA	2,064	2,235	2,379	2,552	2,824
EPS (Bt)	0.37	0.44	0.46	0.48	0.54

Source: KGI Research

Cash Flow


Year to 31 Dec (Bt mn)	2017	2018	2019	2020F	2021F
Operating Cash Flow	1,814	1,618	1,902	2,013	2,225
Net Profit	917	1,089	1,135	1,197	1,359
Depreciation & Amortization	538	576	665	698	733
Change in Working Capital	(1,354)	1,243	(198)	(198)	(198)
Others	1,712	(1,291)	301	316	332
Investment Cash Flow	(2,483)	241	(1,729)	(1,242)	(1,288)
Net CAPEX	(1,090)	(1,232)	(1,741)	(1,794)	(1,848)
Change in LT Investment	(0)	(0)	(0)	(0)	(0)
Change in Other Assets	(1,393)	1,473	12	552	559
Free Cash Flow	(669)	1,859	173	771	937
Financing Cash Flow	642	(1,699)	(27)	(676)	(703)
Change in Share Capital	0	0	0	0	0
Net Change in Debt	(516)	(990)	289	5	15
Change in Other LT Liab.	1,158	(709)	(315)	(681)	(718)
Net Cash Flow	(27)	160	147	95	234

Source: KGI Research

Rates of Return on Invested Capital

Year	1 - $\frac{\text{COGS}}{\text{Revenue}}$	+ $\frac{\text{Depreciation}}{\text{Revenue}}$	+ $\frac{\text{Operating Exp.}}{\text{Revenue}}$	= $\frac{\text{Operating Margin}}{\text{Revenue}}$			
2017	67.2%	7.4%	13.2%	12.1%			
2018	66.8%	7.1%	14.0%	12.0%			
2019	68.2%	7.5%	13.9%	10.5%			
2020F	68.0%	7.5%	13.5%	11.0%			
2021F	67.0%	7.2%	14.0%	11.8%			
Year	1/ $\frac{\text{Working Capital}}{\text{Revenue}}$	+ $\frac{\text{Net PPE}}{\text{Revenue}}$	+ $\frac{\text{Other Assets}}{\text{Revenue}}$	= $\frac{\text{Capital Turnover}}{\text{Revenue}}$			
2017	0.17	1.07	1.75	0.34			
2018	0.21	1.06	1.56	0.35			
2019	0.23	1.08	1.59	0.34			
2020F	0.22	1.05	1.55	0.35			
2021F	0.23	0.98	1.48	0.37			
Year	Operating Margin	x	Capital Turnover	x	Cash Tax Rate	=	After-tax Return on Inv. Capital
2017	12.1%		0.3		80.5%		3.3%
2018	12.0%		0.4		81.4%		3.5%
2019	10.5%		0.3		81.9%		3.0%
2020F	11.0%		0.4		80.0%		3.1%
2021F	11.8%		0.4		80.0%		3.5%

Source: KGI Research

Bangkok Chain Hospital – Recommendation & target price history


Source: KGI Research

Corporate Governance Report of Thai Listed Companies



Companies with Excellent CG Scoring

Stock	Company name	Stock	Company name	Stock	Company name
ADVANC	ADVANCED INFO SERVICE	HMPRO	HOME PRODUCT CENTER	QH	QUALITY HOUSES
ANAN	ANANDA DEVELOPMENT	INTUCH	SHIN CORPORATION	RATCH	RATCHABURI ELECTRICITY GENERATING HOLDING
AOT	AIRPORTS OF THAILAND	IRPC	IRPC	ROBINS	ROBINSON DEPARTMENT STORE
AP	ASIAN PROPERTY DEVELOPMENT	IVL	INDORAMA VENTURES	SAMART	SAMART CORPORATION
BANPU	BANPU	KBANK	KASIKORN BANK	SAMTEL	SAMART TELCOMS
BCP	THE BANGCHAK PETROLEUM	KCE	KCE ELECTRONICS	SCB	THE SIAM COMMERCIAL BANK
BTS	BTS GROUP HOLDINGS	KKP	KIATNAKIN BANK	SCC	THE SIAM CEMENT
CK	CH. KARNCHANG	KTB	KRUNG THAI BANK	SCCC	SIAM CITY CEMENT
CPF	CHAROEN POKPHAND FOODS	KTC	KRUNGTHAI CARD	SPALI	SUPALAI
CPN	CENTRAL PATTANA	LPN	L.P.N. DEVELOPMENT	SPRC	STAR PETROLEUM REFINING
DELTA	DELTA ELECTRONICS (THAILAND)	MINT	MINOR INTERNATIONAL	STEC	SINO-THAI ENGINEERING AND CONSTRUCTION
DTAC	TOTAL ACCESS COMMUNICATION	MONO	MONO TECHNOLOGY	SVI	SVI
EASTW	EASTERN WATER RESOURCES DEVELOPMENT AND MANAGE	PLANB	PLAN B MEDIA	TCAP	THANACHART CAPITAL
EGCO	ELECTRICITY GENERATING	PSH	PRUKSA HOLDING	THCOM	THAICOM
GFPT	GFPT	PTT	PTT	TISCO	TISCO FINANCIAL GROUP
GPSC	GLOBAL POWER SYNERGY	PTTEP	PTT EXPLORATION AND PRODUCTION	TMB	TMB BANK
GUNKUL	GUNKUL ENGINEERING	PTTGC	PTT GLOBAL CHEMICAL	TOP	THAI OIL
HANA	HANA MICROELECTRONICS	PYLON	PYLON	TRUE	TRUE CORPORATION



Companies with Very Good CG Scoring

Stock	Company name	Stock	Company name	Stock	Company name
AAV	ASIA AVIATION	ERW	THE ERAWAN GROUP	SAWAD	SRISAWAD POWER 1979
AMATA	AMATA CORPORATION	GLOBAL	SIAM GLOBAL HOUSE	SCI	SCI ELECTRIC
BBL	BANGKOK BANK	GLOW	GLOW ENERGY	SCN	SCAN INTER
BCPG	BCPG	LH	LAND AND HOUSES	SEAFKO	SEAFKO
BDMS	BANGKOK DUSIT MEDICAL SERVICES	MAJOR	MAJOR CINEPLEX GROUP	SIRI	SANSIRI
BEM	BANGKOK EXPRESSWAY AND METRO	MAKRO	SIAM MAKRO	SMT	STARS MICROELECTRONICS (THAILAND)
CENTEL	CENTRAL PLAZA HOTEL	MALEE	MALEE SAMPRAN	TASCO	TIPCO ASPHALT
CHG	CHULARAT HOSPITAL	MTLS	MUANGTHAI LEASING	TKN	TAOKAENOI FOOD & MARKETING
CKP	CK POWER	NOK	NOK AIRLINES	TVO	THAI VEGETABLE OIL
DCC	DYNASTY CERAMIC	RS	RS	TWPC	THAI WAH



Companies with Good CG Scoring

Stock	Company name	Stock	Company name	Stock	Company name
AMA	AMA MARINE	BPP	BANPU POWER	SQ	SAHAKOL EQUIPMENT
BA	BANGKOK AIRWAYS	CBG	CARABAO GROUP	TPCH	TPC POWER HOLDING
BCH	BANGKOK CHAIN HOSPITAL	LPH	LADPRAO GENERAL HOSPITAL		
BH	BUMRUNGRAD HOSPITAL	SAPPE	SAPPE		

Companies classified Not in the three highest score groups

Stock	Company name	Stock	Company name	Stock	Company name
BGRIM	B. GRIMM POWER	TOA	TOA PAINT (THAILAND)	WHAUP	WHA UTILITIES AND POWER
CPALL	CP ALL	UNIQ	UNIQUE ENGINEERING AND CONSTRUCTION	WORK	WORKPOINT ENTERTAINMENT
THAI	THAI AIRWAYS INTERNATIONAL	WHA	WHA CORPORATION		

Source: www.thai-iod.com

Disclaimer: The disclosure of the survey result of the Thai Institute of Directors Association ("IOD") regarding corporate governance is made pursuant to the policy of the Office of the Securities and Exchange Commission. The survey of the IOD is based on the information of a company listed on the Stock Exchange of Thailand and the Market for Alternative Investment disclosed to the public and able to be accessed by a general public investor. The result, therefore, is from the perspective of a third party. It is not an assessment of operation and is not based on inside information. The survey result is as of the date appearing in the Corporate Governance Report of Thai Listed Companies. As a result, the survey result may be changed after that date or when there is any change to the relevant information. Nevertheless, KGI Securities (Thailand) Public Company Limited (KGI) does not confirm, verify, or certify the accuracy and completeness of such survey result.

Anti-corruption Progress Indicator

Level 5: Extended

Stock	Company name	Stock	Company name	Stock	Company name
CPN	CENTRAL PATTANA	SCC	THE SIAM CEMENT		

Level 4: Certified

Stock	Company name	Stock	Company name	Stock	Company name
ADVANC	ADVANCED INFO SERVICE	IFEC	INTER FAR EAST ENGINEERING	SVI	SVI
BBL	BANGKOK BANK	KBANK	KASIKORN BANK	TCAP	THANACHART CAPITAL
DCC	DYNASTY CERAMIC	KKP	KIATNAKIN BANK	TISCO	TISCO FINANCIAL GROUP
DRT	DIAMOND ROOFING TILES	KTB	KRUNG THAI BANK	TMB	TMB BANK
EGCO	ELECTRICITY GENERATING	MINT	MINOR INTERNATIONAL		
ERW	THE ERAWAN GROUP	SCB	THE SIAM COMMERCIAL BANK		

Level 3: Established

Stock	Company name	Stock	Company name	Stock	Company name
AAV	ASIA AVIATION	DTAC	TOTAL ACCESS COMMUNICATION	PACE	PACE DEVELOPMENT CORPORATION
ANAN	ANANDA DEVELOPMENT	GFPT	GFPT	PS	PRUKSA REAL ESTATE
AP	ASIAN PROPERTY DEVELOPMENT	GL	GROUP LEASE	RATCH	RATCHABURI ELECTRICITY GENERATING HOLDING
BA	BANGKOK AIRWAYS	GLOW	GLOW ENERGY	ROBINS	ROBINSON DEPARTMENT STORE
BDMS	BANGKOK DUSIT MEDICAL SERVICES	GPSC	GLOBAL POWER SYNERGY	SAMART	SAMART CORPORATION
BIGC	BIG C SUPERCENTER	HMPRO	HOME PRODUCT CENTER	SPALI	SUPALAI
BJCHI	BJC HEAVY INDUSTRIES	KTC	KRUNGTHAI CARD	STEC	SINO-THAI ENGINEERING AND CONSTRUCTION
CENTEL	CENTRAL PLAZA HOTEL	LPN	L.P.N. DEVELOPMENT	TASCO	TIPCO ASPHALT
CHG	CHULARAT HOSPITAL	MAKRO	SIAM MAKRO	TMT	THAI METAL TRADE
CK	CH. KARNCHANG	MODERN	MODERNFORM GROUP	TPCH	TPC POWER HOLDING
CKP	CK POWER	NOK	NOK AIRLINES	WHA	NOK AIRLINES

Level 2: Declared

Stock	Company name	Stock	Company name	Stock	Company name
AOT	AIRPORTS OF THAILAND	GUNKUL	GUNKUL ENGINEERING	QH	QUALITY HOUSES
BH	BUMRUNGRAD HOSPITAL	ILINK	INTERLINK COMMUNICATION	TRT	TIRATHAI
GLOBAL	SIAM GLOBAL HOUSE	MTLS	MUANGTHAI LEASING	TVO	THAI VEGETABLE OIL

Level 1: Committed

Stock	Company name	Stock	Company name	Stock	Company name
CBG	CARABAO GROUP	RS	RS	SAWAD	SRIAWAD POWER 1979
MAJOR	MAJOR CINEPLEX GROUP				

No progress

Stock	Company name	Stock	Company name	Stock	Company name
BCH	BANGKOK CHAIN HOSPITAL	CPALL	CP ALL	WORK	WORKPOINT ENTERTAINMENT
BEM	BANGKOK EXPRESSWAY AND METRO	LPH	LADPRAO GENERAL HOSPITAL		

Source: www.cgthailand.org

Disclaimer: The disclosure of the Anti-Corruption Progress Indicators of a listed company on the Stock Exchange of Thailand, which is assessed by the relevant institution as disclosed by the Office of the Securities and Exchange Commission, is made in order to comply with the policy and sustainable development plan for the listed companies. The relevant institution made this assessment based on the information received from the listed company, as stipulated in the form for the assessment of Anti-corruption which refers to the Annual Registration Statement (Form 56-1), Annual Report (Form 56-2), or other relevant documents or reports of such listed company. The assessment result is therefore made from the perspective of a third party. It is not an assessment of operation and is not based on any inside information. Since this assessment is only the assessment result as of the date appearing in the assessment result, it may be changed after that date or when there is any change to the relevant information. Nevertheless, KGI Securities (Thailand) Public Company Limited (KGI) does not confirm, verify, or certify the accuracy and completeness of the assessment result.

KGI Locations

China	Shanghai	Room 1507, Park Place, 1601 Nanjing West Road, Jingan District, Shanghai, PRC 200040
	Shenzhen	Room 24D1, 24/F, A Unit, Zhen Ye Building, 2014 Bao'annan Road, Shenzhen, PRC 518008
Taiwan	Taipei	700 Mingshui Road, Taipei, Taiwan Telephone 886.2.2181.8888 · Facsimile 886.2.8501.1691
Hong Kong		41/F Central Plaza, 18 Harbour Road, Wanchai, Hong Kong Telephone 852.2878.6888 Facsimile 852.2878.6800
Thailand	Bangkok	8th - 11th floors, Asia Centre Building 173 South Sathorn Road, Bangkok 10120, Thailand Telephone 66.2658.8888 Facsimile 66.2658.8014
Singapore		4 Shenton Way #13-01 SGX Centre 2 Singapore 068807 Telephone 65.6202.1188 Facsimile 65.6534.4826

KGI's Ratings

Rating	Definition
Outperform (OP)	The stock's excess return over the next twelve months is ranked in the top 40% of KGI's coverage universe in the related market (e.g. Taiwan).
Neutral (N)	The stock's excess return over the next twelve months is ranked in the range between the top 40% and the bottom 40% of KGI's coverage universe in the related market (e.g. Taiwan)
Under perform (U)	The stock's excess return over the next twelve months is ranked in the bottom 40% of KGI's coverage universe in the related market (e.g. Taiwan).
Not Rated (NR)	The stock is not rated by KGI.
Restricted (R)	KGI policy and/or applicable law regulations preclude certain types of communications, including an investment recommendation, during the course of KGI's engagement in an investment banking transaction and in certain other circumstances. <i>Excess return = 12M target price/current price-</i>
Note	When an analyst publishes a new report on a covered stock, we rank the stock's excess return with those of other stocks in KGI's coverage universe in the related market. We will assign a rating based on its ranking. If an analyst does not publish a new report on a covered stock, its rating will not be changed automatically.

Disclaimer

KGI Securities (Thailand) Plc. ("The Company") disclaims all warranties with regards to all information contained herein. In no event shall the Company be liable for any direct, indirect or any damages whatsoever resulting from loss of income or profits, arising by utilization and reliance on the information herein. All information hereunder does not constitute a solicitation to buy or sell any securities but constitutes our sole judgment as of this date and are subject to change without notice.